Article

Dr. Jill Lacy Named 2021 ASCO Fellow

Jill Lacy, MD, Professor of Medicine at Yale Cancer Center, was named a Fellow of the American Society of Clinical Oncology.

Jill Lacy, MD, Professor of Medicine (Medical Oncology) at Yale Cancer Center,

Jill Lacy, MD

Jill Lacy, MD, Professor of Medicine (Medical Oncology) at Yale Cancer Center, was named a Fellow of the American Society of Clinical Oncology (FASCO). The FASCO distinction honors members of the American Society of Clinical Oncology (ASCO) for their extraordinary volunteer service, commitment, and dedication to the organization. Lacy was one of 34 recipients nationwide to earn the FASCO designation this year.

“The recipients of this year’s Special Awards have made exceptional contributions to the oncology community,” said Monica Bertagnolli, MD, FACS, FASCO, Past President of ASCO and Chair of the Joint Special Awards Selection Committee in an online announcement. “It is our honor to recognize their commitment to transforming cancer care and improving quality of life for people living with cancer.”

ASCO represents nearly 45,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. It is supported by its affiliate organization, the Conquer Cancer Foundation.

This year’s Fellows of ASCO will be officially conferred the FASCO status at the 2021 annual meeting held June 4-8.

About Yale Cancer Center and Smilow Cancer Hospital
Yale Cancer Center (YCC) is one of only 51 National Cancer Institute-designated comprehensive cancer centers in the nation and the only such center in Connecticut. Cancer treatment for patients is available at Smilow Cancer Hospital through 13 multidisciplinary teams and at 15 Smilow Cancer Hospital Care Centers in Connecticut and Rhode Island. Comprehensive cancer centers play a vital role in the advancement of the NCI’s goal of reducing morbidity and mortality from cancer through scientific research, cancer prevention, and innovative cancer treatment.

Related Videos
David Rimm, MD, PhD, discusses current HER2 immunohistochemistry assays that are used in the management of breast cancer, and their shortcomings.
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
David Rimm, MD, PhD
A panel of 3 experts on nasopharyngeal carcinoma
David Rimm, MD, PhD
A panel of 3 experts on nasopharyngeal carcinoma
A panel of 3 experts on nasopharyngeal carcinoma
A panel of 3 experts on nasopharyngeal carcinoma
A panel of 3 experts on nasopharyngeal carcinoma
A panel of 3 experts on nasopharyngeal carcinoma